As treatment of metastatic melanoma increasingly involves combination therapies, it will be of great interest to define which combinations of miR-7-5p and targeted therapies (BRAF/MEK inhibitors) or immunotherapies are most effective or yield synergistic anti-melanoma effects. Here, MAP2K7 is linked to melanoma.